Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Oxford Biomedica News

    2,52 € +8,62% +0,20 €
    09:17:28 Uhr Frankfurt aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2JLRX
    ISIN: GB00BDFBVT43
    US-Symbol: OXBDF
    Typ: Aktie

    Oxford Biomedica News

    28.05.21 - DGAP
    Oxford Biomedica (OXB): Driving innovation in a thriving CGT industry
    Edison Investment Research Limited Oxford Biomedica (OXB): Driving innovation in a thriving CGT industry 28-May-2021 / 07:00 GMT/BST London, UK, 28 May 2021 Oxford ...
    05.10.20 - DGAP
    Edison Investment Research Limited: Oxford Biomedica (OXB): Vector innovation key to cell and gene evolution
    Edison Investment Research Limited Edison Investment Research Limited: Oxford Biomedica (OXB): Vector innovation key to cell and gene evolution 05-Oct-2020 / 10:59 GMT/BST ...
    05.10.20 - ACCESSWIRE
    Oxford Biomedica (OXB): Vector Innovation Key to Cell and Gene Evolution
    LONDON, UK / ACCESSWIRE / October 5, 2020 / Oxford Biomedica (OXB) is a pioneer and global leader in the development and manufacture of commercial-​scale lentiviral vectors ...
    04.06.19 - ACCESSWIRE
    Edison Issues Outlook on Oxford Biomedica (OXB)
    LONDON, UK / ACCESSWIRE / June 4, 2019 / Oxford Biomedica (LSE: OXB) is a pioneer and global leader in the development and manufacture of commercial-​scale lentiviral ...
    15.02.18 - PR Newswire
    Oxford BioMedica Announces Collaboration and Licence Agreement with Bioverativ in the Field of Haemophilia Gene Therapy
    Oxford BioMedica Announces Collaboration and Licence Agreement with Bioverativ in the Field of Haemophilia Gene Therapy PR Newswire
    08.08.12 - PR Newswire
    Oxford BioMedica Announces Positive DSMB Review of Ongoing RetinoStat® and StarGen™ Clinical Studies
    Oxford BioMedica Announces Positive DSMB Review of Ongoing RetinoStat® and StarGen™ Clinical Studies PR Newswire
    23.07.12 - PR Newswire
    Oxford BioMedica Receives Funding Award from the Foundation Fighting Blindness for ongoing UshStat® Phase I/IIa study
    Oxford BioMedica Receives Funding Award from the Foundation Fighting Blindness for ongoing UshStat® Phase I/IIa study PR Newswire
    10.07.12 - PR Newswire
    Oxford BioMedica Announces Initiation of Phase II Collaborative Study for TroVax® in Colorectal Cancer
    Oxford BioMedica Announces Initiation of Phase II Collaborative Study for TroVax® in Colorectal Cancer PR Newswire

    Newssuche

    Videos

    newspaper
    09:10 Uhr -3,35%
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: UH45D5 Hebel: 2,11 Laufzeit: OpenEnd Einstieg: Market ... Mehr »